Compare RCEL & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCEL | BIOA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.3M | 175.7M |
| IPO Year | N/A | 2024 |
| Metric | RCEL | BIOA |
|---|---|---|
| Price | $3.52 | $12.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $11.75 | $11.33 |
| AVG Volume (30 Days) | 201.4K | ★ 403.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $72,401,000.00 | $5,917,000.00 |
| Revenue This Year | $13.12 | N/A |
| Revenue Next Year | $27.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.59 | N/A |
| 52 Week Low | $3.33 | $2.88 |
| 52 Week High | $14.16 | $13.10 |
| Indicator | RCEL | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 83.65 |
| Support Level | $3.33 | $12.00 |
| Resistance Level | $3.58 | $13.10 |
| Average True Range (ATR) | 0.18 | 0.72 |
| MACD | 0.01 | 0.32 |
| Stochastic Oscillator | 22.31 | 97.20 |
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.